Ensoma
Pre-clinicalOur technology platform enables in vivo engineering of hematopoietic stem cells (HSCs). It combines an off-the-shelf in vivo delivery system with a state-of-the-art gene engineering toolkit. Our vision is for an HSC engineering platform that selectively and durably modifies cells of the hematopoietic system with the intent to treat diseases with unprecedented versatility – all with a one-time treatment regimen.
About
Our technology platform enables in vivo engineering of hematopoietic stem cells (HSCs). It combines an off-the-shelf in vivo delivery system with a state-of-the-art gene engineering toolkit. Our vision is for an HSC engineering platform that selectively and durably modifies cells of the hematopoietic system with the intent to treat diseases with unprecedented versatility – all with a one-time treatment regimen.
Funding History
2Total raised: $205M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile